Roche Q1 sales up 7% on drugs Phesgo, Vabysmo
Finance

Roche Q1 sales up 7% on drugs Phesgo, Vabysmo

Published by Global Banking & Finance Review

Posted on April 24, 2025

1 min read

· Last updated: January 24, 2026

Add as preferred source on Google

Roche's Q1 Sales Climb 7% on Strong Drug Performance

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair.

Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts.

Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage.

(Reporting by Ludwig Burger, Editing by Rachel More)

Key Takeaways

  • Roche's Q1 sales increased by 7%, surpassing forecasts.
  • Key drivers were Phesgo, Vabysmo, and Xolair.
  • Quarterly revenues reached 15.44 billion Swiss francs.
  • Market expectations were slightly exceeded.
  • Roche targets high single-digit EPS growth for the year.

Frequently Asked Questions

What is the main topic?
The article discusses Roche's Q1 sales increase driven by drugs Phesgo and Vabysmo, surpassing market expectations.
Another relevant question?
What drugs contributed to Roche's sales growth? Phesgo, Vabysmo, and Xolair were key contributors.
Third question about the topic?
What are Roche's future financial targets? Roche aims for high single-digit EPS growth this year.

Related Articles

More from Finance

Explore more articles in the Finance category